Get our latest issue now

available for iOS, Android & web

latest issue

Latest issue

March issue of PharmaTimes Magazine is out now

How to… / Hold an inspirational meeting

We take a look at some innovative alternatives

SmartTech / Droning on
Could drones have a place in healthcare? We investigate

SmartDeals
Last month’s SmartDeals

Talkback
You let us know your thoughts

Health Policy
we take a look at EU clinical trials transparency

#PTSocial
News from the technology and marketing world

Business Insight / Royal Bank of Scotland: “no two businesses are the same”
RBS’ pharma team talks to us about how they are continuing to support the industry – with specialist insight

Cover story/Adherence / Use it or lose it
It doesn’t matter how good your medicine is or how well it performs in clinical trials if patients aren’t taking it as recommended

Medicines Optimisation / Taking your medicine
Is the current healthcare system helping or hindering medicines optimisation?

Health Focus / The challenge of schizophrenia
There is still much to be done to help patients with this disease

Emerging Markets / MINT Selection
Forget BRIC, the new acronym is MINT – Mexico, Indonesia, Nigeria, Turkey – as the latest emerging markets on pharma’s radar

Business Insight / Ashfield Healthcare – supporting customer and patient outcomes
What makes Ashfield Healthcare unique?

Patient Files / “Think of us as partners and not as subjects”
One patient’s experience of being diagnosed with whooping cough

Click here to see the latest PharmaTimes Magazine

To subscribe go to www.pharmatimes.com/subscribe; digital available from:

download on the app store get it on google play

Outcomes: a gamechanger for pharma

Patient-recorded outcome measures are likely to become a key part of how healthcare is provided, funded and managed. But is industry ready?

Healthcare Writer Lynne Taylor

The British government’s determination to place health outcomes at the heart of NHS decision-making presents UK-based drugmakers with a unique and potentially huge advantage over their global competitors.

Working in collaboration with the NHS to identify a product’s true value – in other words its value to the patient – has the potential to boost levels of medicines uptake and could also lead to products arriving earlier to market, both in the UK and overseas, a PharmaTimes business meeting was told recently. Leading these potentially game-changing opportunities is the NHS patient-recorded outcome measures programme, which began in 2009.

Innovative drugmakers have included PROMs in their clinical trials for many years, and the data have also long been used in observational studies and population health surveys. “We have decades of experience using these instruments and pharma is way ahead of the game. The fact they are now being measured in healthcare systems changes everything,” Professor Nancy Devlin, research director at the Office of Health Economics told the meeting. Indeed, PROMs are likely to become a key part of how all healthcare is provided, funded and managed, The King’s Fund healthcare policy think-tank has forecast.

So what exactly are PROMs and why should this matter to pharma? You can find out by reading the full article online here

See what's coming up in the March issue [PDF]

Visions 2014 supplement

Contents:

R&D
Creating a balance between
reimbursement and innovation

Real-world data
How to plan early

NHS reform
What more does pharma need to do?

PharmaTweets
We asked you what the big developments in 2014 will be?

Change is key to opportunity
What to adapt for

Salesforce effectiveness
Future-proofing the sales team

Myeloma research
An example of a new R&D model

Soundbites
Visions in a nutshell

The complete Visions 2014 supplement PDF is available to download

 

Subscription is free to qualifying UK subscribers

To read articles in full and features in the magazine, why not subscribe

Reprints available.

Average circulation Jan - Dec 2013: 23,178

Find a job

Website Search


Search News Search Magazine
 
Elert Signup!